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room visits (ER), hospitalizations (HOS) using medical claims
data, and prescription costs (Rx) using pharmacy claims data.
Analysis of covariance was used to determine differences in
health care use and expenditures, adjusting for age, gender, and
number of co-morbidities. RESULTS: There were 13,796 partici-
pants in the analysis. Baseline characteristics (age, gender, and
number of co-morbidities) were comparable in the two groups
after matching. Eighty percent of migraine participants identiﬁed
were female. Analyses involving the complete models showed
that migraineurs incurred signiﬁcantly higher expenditure than
non-migraineurs. After adjusting for age, sex and number of
co-morbidities, migraineurs had signiﬁcantly more ER visits per
year (0.7 vs. 0.2, p < 0.0001). Annual ER, HOS, and Total
expenditures were signiﬁcantly higher in the Migraine cohort
(ER: $480 vs. $125, p < 0.0001 and HOS: $980 vs. $588,
p < 0.00001 and Total: $4233 vs. $2004, p < 0.0001). CON-
CLUSION: Migraine patients utilize more health care resources
and incur higher health care expenditures. Study ﬁndings high-
light the beneﬁts to be realized by managing individuals with
migraine.
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OBJECTIVE: Medication non-adherence among patients with
chronic conditions can have both clinical and economic conse-
quences. The objective is to investigate whether non-adherence to
antiepileptic drugs (AEDs) is associated with increased morbidity
relative to adherence, as proxied by health care utilization and
costs, in a Medicaid population with epilepsy. METHODS: A
retrospective open-cohort design using state Medicaid claims
data from Florida, Iowa and New Jersey in the period of January
1997–June 2006 was employed. Patients aged 18 with 1
diagnosis of epilepsy, 1 neurologist visit, 2 AED dispensings,
and 6 months of baseline period were included. Medication
possession ratio (MPR) was used to evaluate AED adherence on
a quarterly basis with MPR 0.8 considered adherent and <0.8
non-adherent. The association of non-adherence with health
care utilization was assessed using univariate and multivariate
Poisson regressions to model frequency of hospitalizations, inpa-
tient days, emergency room (ER), and outpatient visits per
person-year of observation. Quarterly per-patient inpatient, out-
patient, ER, and pharmacy costs were calculated across non-
adherent and adherent quarters for the under-65 population and
cost differences computed. Adjusted incremental costs of non-
adherence were estimated with multivariate Tobit regression
models. RESULTS: A total of 33,658 patients met the study
inclusion criteria (28,470 under-65), together contributing
388,564 (74%) adherent and 136,550 (26%) non-adherent quar-
ters. Non-adherence was associated with signiﬁcantly higher
incidence of hospitalizations (incidence rate ratio [IRR] = 1.39,
95% conﬁdence interval [CI] = 1.37–1.41), inpatient days
(IRR = 1.76, 95% CI = 1.75–1.78), and ER visits (IRR = 1.19.
95% CI = 1.18–1.21). Non-adherence was associated with posi-
tive quarterly incremental costs related to serious outcomes,
including inpatient ($4320, 95% CI = $4077–$4564) and ER
($303, 95% CI = $273–$334) services. CONCLUSION: Non-
adherence to AEDs is relatively common and appears to be
associated with increased morbidity as represented by higher
health care utilization and costs.
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OBJECTIVE: Our study explores the relationship between
30-day and 90-day pharmacy dispensing systems and patient
medication compliance, persistency, and ﬁnancial incentive.
METHODS: Retrospective pharmacy claims data of multiple
sclerosis (MS) patients using four different medications were
extracted from a pharmacy database. Patients were followed
one year. Compliance was measured using the medication pos-
session ratio (MPR), calculated using the ISPOR method. Anni-
versary method and Kaplan-Meier survival curves were applied
to describe patients’ persistency. Associations with drop-off and
different systems were assessed using Cox regression model.
Wilcoxon-Mann-Whitney test was used to compare the mean
patient out-of-pocket and payers’ costs for two systems.
RESULTS: Study sample consisted of 29,808 eligible MS
patients predominantly female (77.01%), mean age of 48.4
years. Therapy-speciﬁc MPRs on the 30-day and the 90-day
system, respectively, were 89.39% and 93.77% with a hazard
ratio (HR) for drop-off of 1.657 for Interferon beta-1a
(Avonex), 82.72% vs. 88.92% (HR = 1.486) for Interferon
beta-1b, 81.48% vs. 88.21% (HR = 1.480) for glatiramer
acetate and 87.46% vs. 90.73% (HR = 1.606) for Interferon
beta-1a (Rebif). Overall MPR comparison between 30-day and
90-day was 85.55% vs. 90.79% (HR = 1.557). Cost per dose
for patients out-of-pocket and payers for a 30-day supply was
$70.78 and $1402.10, respectively. In contrast, a 90-day supply
was $30.59 and $1404.70, respectively. Signiﬁcance tests
showed the comparison was statistically signiﬁcant at level
0.05, except comparison between payer’s costs with a p-value
of 0.46. CONCLUSION: MS patients using 90-day have higher
MPR than patients using 30-day. The patients using 30-day are
more likely to drop off, with a 55.7% higher risk of discon-
tinuation. Results suggest that providing a 90-day supply
improves MS patients’ compliance and persistency within the
one-year study period. Patients spend less when using 90-day
system. Future study focuses on pharmacoeconomic impact of
the dispensing system, incorporating outcome variables for MS
patients’ quality of life.
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OBJECTIVE: To examine compliance rates, measured with the
medication possession ratio (MPR) and 12-month persistence
rates of patients initiating 1 of 4 immunomodulating treatments
for multiple sclerosis (MS). METHODS: The study population
consisted of patients aged 18–64 years initiating MS treatment
from January 2, 2004, to July 5, 2005. Patients were identiﬁed
from an administrative claims database (PharMetrics, Inc.,
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Watertown, MA). Patients had continuous health plan enroll-
ment for12 months before and15 months after their ﬁrst MS
prescription. The proportion of patients with MPR >85%
(appropriate compliance) and 12-month persistence rates (pro-
portion of patients with drug therapy at month 12 without a
lapse of therapy >90 d) were evaluated across 4 treatment
groups: interferon beta (IFNb)-1a subcutaneous (SC), IFNb-1a
intramuscular (IM), IFNb-1b, and glatiramer acetate (GA).
Treatment comparisons were evaluated by using Wilcoxon rank
sum and chi-square tests for continuous and dichotomous vari-
ables, respectively. RESULTS: Immunomodulating treatment was
initiated in 3195 patients (IFNb-1a SC, n = 799; IFNb-1a IM,
n = 905; IFNb-1b, n = 344, and GA, n = 1147). Sex, geographic
region, and health plan and product types were similar across
all treatment groups. Mean age was statistically higher in the
IFNb-1a IM groups vs the IFNb-1a SC and GA groups (44.9 vs
43.5 and 43.8 y, respectively, P < 0.01) but not with the IFNb-1b
group (44.4 y). Compliance (MPR  85%) was signiﬁcantly
higher with IFNb-1a SC vs IFNb-1b (49.7% vs 39.8%;
P = 0.002) but not with GA (45.7%) or IFNb-1a IM (48.1%).
IFNb-1a SC patients had a persistence rate of 60.3%, signiﬁ-
cantly higher than that of IFNb-1a IM (54.9%) and IFNb-1b
(52.9%; P < 0.03, for both) but not GA (60.5%; P = 0.936).
CONCLUSION: All 4 groups were comparable in terms of
demographic characteristics. Although differences in compliance
were less pronounced, the IFNß-1a SC and GA treatment groups
had the highest persistence rates.
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OBJECTIVE: This study examined the relationship between
medication gaps and severe MS relapses. METHODS: Subjects
were selected from the PHARMetrics database if they had at least
one MS drug (Avonex®, Betaseron®, Copaxone®, Rebif®)
claim from January 1, 2000 through December 31, 2004, and,
were continuously eligible for 24-months following their ﬁrst
disease modifying prescription (index date), in addition to
6-months prior to the index date. Subjects were excluded if the
were <18 or >65 years of age, exposed to Tysabri® after the
index date, had evidence of study medication use in a health care
facility, or lived in a long-term care facility. A severe MS relapse
was deﬁned as an “MS-related” hospitalization or emergency
room visit. Maximum gap in therapy (Maxgap), was deﬁned as
the longest continuous period with no evidence of study medi-
cation availability (based on dispensing date and days supply).
Maxgap was categorized as 0–10 days, 11–89 days, and 90+
days. Covariates included, age, gender, region, and treatment
status (new or existing), comorbidities, and therapy type (mono-
or multi-drug therapy). RESULTS: Subjects (N = 2388) had a
mean age of 43.9 years, 76.7% were new patients, 8.1% had at
least 1 severe MS relapse over the 24-month study period, and
76.4% were female. Maxgap had a signiﬁcant odds ratio (OR) of
1.925 (p = 0.007) for the 90+ day group (0–10 day reference).
Monotherapy use for the 4 study drugs was associated with
reduced risk of severe relapse (ORs between 0.450 and 0.552).
Other signiﬁcant covariates were comorbidity and East region
(ORs = 1.090 and 1.495 respectively). Age, gender, and the other
regions were not signiﬁcant at alpha = 0.05. CONCLUSION:
Gaps in MS drug therapy longer than 90 days are associated with
a higher risk of severe MS relapse compared to short or no gaps
in treatment.
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OBJECTIVE: The objective of this analysis was to evaluate the
effect of botulinum toxin type A on quality of life in patients
with cervical dystonia. METHODS: The study consisted of
a 10-week, nonrandomized, open-label period followed by
a 10-week, randomized, double-blind, placebo-controlled, mul-
ticenter, parallel-group period. Patients were randomized to
receive either botulinum toxin type A, at a dose determined by
the physician based on the patient’s established prestudy treat-
ment regimen and the patient’s presentation, or placebo. Patients
completed the SF-36 Health Survey to evaluate the following
quality of life attributes: physical functioning, role limitations
due to physical health, role limitations due to emotional prob-
lems, energy/fatigue, emotional well-being, social functioning,
pain, and general health. RESULTS: A total of 170 patients were
randomized to treatment. A signiﬁcant difference was seen in the
change from week 0 to week 6 for the physical functioning
domain in which the botulinum toxin group had a mean change
of 2.00 (improvement) and the placebo group had a mean change
of -3.03 (worsening) (P = 0.036). Botulinum toxin produced
greater improvement than placebo for all other domains except
social functioning; however, the differences between groups were
not signiﬁcantly different. Rates of adverse events were nearly
equivalent between groups (59.1% BoNT-A vs. 58.5% placebo
group). CONCLUSION: Prior literature indicates that the SF-36
is not a sensitive measure of the change in quality of life due to
treatment in the cervical dystonia population. Despite this, the
botulinum toxin type A treatment group showed signiﬁcantly
improved physical functioning. Furthermore, important trends
were identiﬁed in other domains.
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OBJECTIVE: Migraine, affecting 11% of the US population, is a
vastly under diagnosed and underreported disease. Migraine can
impact patients’ work and studies, family relationships, social
relationships and emotional well-being thus undermining quality
of life. A review of quality of life instruments in migraine is
summarized. METHODS: Review of literature using Pubmed
with combinations of search terms ‘migraine’, ‘quality of life’,
‘questionnaire’ was conducted. Articles were selected based on
measurement of disability or quality of life in migraine. Fields
extracted from articles for each instrument and on the basis of
which analyzed included name and type of instrument, appli-
cable age group, types of respondent, means of administration,
items and domains, scaling, item selection and psychometric
properties. Pediatric versions of questionnaires were not included
in the study. RESULTS: Of the instruments that were identiﬁed 3
were generic, 11 were migraine speciﬁc questionnaires for quality
of life in migraine and 3 were migraine speciﬁc questionnaires
testing patients’ response to therapy. The average age of partici-
pants ranged from 36.5 years to 44 years. The items varied in
Abstracts A145
